N
BTAI icon

Nuveen’s BioXcel Therapeutics BTAI Stock Holding History

Nuveen’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-926
Closed -$43.7K – 3281
2023
Q4 		$43.7K Hold
926
– – ﹤0.01% 3306
2023
Q3 		$37.5K Hold
926
– – ﹤0.01% 3163
2023
Q2 		$98.6K Sell
926
-2,908
-76% -$968K ﹤0.01% 3169
2023
Q1 		$1.15M Sell
3,834
-8,941
-70% -$3.82M ﹤0.01% 2560
2022
Q4 		$4.39M Sell
12,775
-827
-6% -$200K ﹤0.01% 1988
2022
Q3 		$2.57M Buy
13,602
+6,645
+96% +$1.54M ﹤0.01% 2269
2022
Q2 		$1.47M Buy
6,957
+3,394
+95% +$714K ﹤0.01% 2604
2022
Q1 		$958K Sell
3,563
-201
-5% -$58.3K ﹤0.01% 2830
2021
Q4 		$1.22M Buy
3,764
+856
+29% +$367K ﹤0.01% 2784
2021
Q3 		$1.43M Sell
2,908
-580
-17% -$255K ﹤0.01% 2827
2021
Q2 		$1.62M Buy
3,488
+145
+4% +$79K ﹤0.01% 2803
2021
Q1 		$2.31M Sell
3,343
-99
-3% -$79.6K ﹤0.01% 2547
2020
Q4 		$2.54M Sell
3,442
-2,439
-41% -$1.9M ﹤0.01% 2393
2020
Q3 		$4.08M Sell
5,881
-3,807
-39% -$2.86M ﹤0.01% 2030
2020
Q2 		$8.22M Buy
9,688
+54
+0.6% +$35.2K ﹤0.01% 1623
2020
Q1 		$3.44M Buy
9,634
+8,966
+1,342% +$3.22M ﹤0.01% 1909
2019
Q4 		$156K Hold
668
– – ﹤0.01% 3095
2019
Q3 		$75K Hold
668
– – ﹤0.01% 3180
2019
Q2 		$117K Buy
+668
New +$113K ﹤0.01% 3213

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen's BTAI Position: Q1 2024 in Review

Nuveen sold out of BioXcel Therapeutics (BTAI) in Q1 2024, closing a stake of 926 shares — an estimated $43.7K sold.

Nuveen first reported a position in BTAI in Q2 2019 and held it in 19 quarters. The position peaked at $8.22M in Q2 2020. 73 funds tracked by Wall St. Rank hold BTAI as of Q1 2024.

  • Nuveen reported no remaining BioXcel Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Nuveen sold 926 BioXcel Therapeutics shares in Q1 2024, an estimated $43.7K.
  • Nuveen first reported a position in BioXcel Therapeutics in Q2 2019 and held it in 19 quarters.
  • Nuveen's BioXcel Therapeutics position peaked at $8.22M in Q2 2020.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2024.

Based on Nuveen's 13F filing for Q1 2024, filed 13 May 2024.